Gerds AT,Dao KH .2017 .Polycythemia vera management and challenges in the community health setting. Oncology, 92(4) : 179-89.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM,Bloomfield CD,Cazzola M,Vardiman JW . .The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. -03-643544., 127(20) : 2391-405.
Mehta J,Wang H,Iqbal SU,Mesa R .2013 .Epidemiology of myeloproliferative neoplasms in the United States. Leukemia & lymphoma. 2014 Mar, 813500(3) : 595-600.
Emanuel RM,Dueck AC,Geyer HL,Kiladjian JJ,Slot S,Zweegman S,Te Boekhorst PA,Commandeur S,Schouten HC,Sackmann F,Fuentes AK .2012 .Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. 2012 Nov, 42(33) : 4098.
Tefferi A,Vardiman JW . .Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. , 2404955(1) : 14-22.
JL Spivak . .Polycythemia vera: myths, mechanisms, and management. -12-0349., 100(13) : 4272-90.
Kumar C,Purandare AV,Lee FY,Lorenzi MV .2009 .Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene, 107(24) : 2305-13.
Hensley B,Geyer H,Mesa R .2013 .Polycythemia vera: current pharmacotherapy and future directions. Expert opinion on pharmacotherapy. 2013 Apr, 779671(5) : 609-17.
Scherber R,Dueck A,Johansson PL,Barbui T,Barosi G,Vannucchi AM,Passamonti F,Andreasson B,Ferarri ML,Rambaldi A,Samuelsson J. .2010 .The myeloproliferative neoplasm symptom assessment form (MPN-SAF): an international prospective validation trial in 402 patients. , 21(21) : 4095-95.
Griesshammer M,Gisslinger H,Mesa R . .Current and future treatment options for polycythemia vera. 2015 Jun, 1(6) : 901-10.
Tefferi A,Rumi E,Finazzi G,Gisslinger H,Vannucchi AM,Rodeghiero F,Randi ML,Vaidya R,Cazzola M,Rambaldi A,Gisslinger B .2013 .Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 163(9) : 1874-81.
Tefferi A,Barbui T. . .Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management. American journal of hematology, 94(1) : 133-43.
Spivak JL . .Polycythemia vera. Current treatment options in oncology. 2018 Feb, 1(2) : 12.
Tefferi A,Guglielmelli P,Larson DR,Finke C,Wassie EA,Pieri L,Gangat N,Fjerza R,Belachew AA,Lasho TL,Ketterling RP . .Longterm survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct, 124(16) : 2507-13.
Hultcrantz M,Kristinsson SY,Andersson TM,Landgren O,Eloranta S,Derolf ÅR,Dickman PW,Björkholm M. .1925 .Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. 2012 Aug, 42(24) : 2995.
Cerquozzi S,Tefferi A .2015 .Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. 2015 Nov;, 95(11) : e366.
Barbui T,Vannucchi AM,Carobbio A,Thiele J,Rumi E,Gisslinger H,Rodeghiero F,Randi ML,Rambaldi A,Pieri L,Pardanani A . .Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis. American journal of hematology, 90(5) : 434-7.
Finazzi G. .2004 .A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). 2004 Jun, 02(5) : 285-8.
Marchioli R,Finazzi G,Landolfi R,Kutti J,Gisslinger H,Patrono C,Marilus R,Villegas A,Tognoni G,Barbui T. .2005 .Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. 2005 Apr, 07(10) : 2224-32.
Bonicelli G,Abdulkarim K,Mounier M,Johansson P,Rossi C,Jooste V,Andreasson B,Maynadié M . .Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients. British journal of haematology, 160(2) : 251-4.
Landolfi R,Di Gennaro L,Barbui T,De Stefano V,Finazzi G,Marfisi R,Tognoni G,Marchioli R . .Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. -08- 042515., 15(6) : 2446-52.
McMullin MF,Harrison CN,Kiladjian JJ . .Treatment target in polycythemia vera. 2013 Apr, 1(16) : 1554-5.
Tefferi A,Vannucchi AM,Barbui T. . .Blood cancer journal. 2018 Jan, 10(1) : 1-7.